|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu
L and He J: Report of incidence and mortality in China cancer
registries, 2009. Chin J Cancer Res. 25:10–21. 2013.PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Modolell I, Guarner L and Malagelada JR:
Vagaries of clinical presentation of pancreatic and biliary tract
cancer. Ann Oncol. 10 Suppl 4:S82–S84. 1999. View Article : Google Scholar
|
|
5
|
Cartwright T, Richards DA and Boehm KA:
Cancer of the pancreas: Are we making progress? A review of studies
in the US Oncology Research Network. Cancer Control. 15:308–313.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paulson AS, Cao HS Tran, Tempero MA and
Lowy AM: Therapeutic advances in pancreatic cancer.
Gastroenterology. 144:1316–1326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ansari D, Gustafsson A and Andersson R:
Update on the management of pancreatic cancer: Surgery is not
enough. World J Gastroenterol. 21:3157–3165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Puleo F, Maréchal R, Demetter P, Bali MA,
Calomme A, Closset J, Bachet JB, Deviere J and Van Laethem JL: New
challenges in perioperative management of pancreatic cancer. World
J Gastroenterol. 21:2281–2293. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Greer JB, Lynch HT and Brand RE:
Hereditary pancreatic cancer: A clinical perspective. Best Pract
Res Clin Gastroenterol. 23:159–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Szafranska AE, Davison TS, John J, Cannon
T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA
expression alterations are linked to tumorigenesis and
non-neoplastic processes in pancreatic ductal adenocarcinoma.
Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Q, Wei L, Guan X, Wu Y, Zou Q and Ji
Z: Briefing in family characteristics of microRNAs and their
applications in cancer research. Biochim Biophys Acta.
1844:191–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li M, Fu W, Wo L, Shu X, Liu F and Li C:
miR-128 and its target genes in tumorigenesis and metastasis. Exp
Cell Res. 319:3059–3064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaplan BB, Kar AN, Gioio AE and Aschrafi
A: MicroRNAs in the axon and presynaptic nerve terminal. Front Cell
Neurosci. 7:1262013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang W, Liu M, Xu J, Fu H, Zhou B, Yuan T
and Chen P: MiR-377 inhibits the proliferation of pancreatic cancer
by targeting Pim-3. Tumour Biol. 37:14813–14824. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoo HI, Kim BK and Yoon SK:
MicroRNA-330-5p negatively regulates ITGA5 expression in human
colorectal cancer. Oncol Rep. 36:3023–3029. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeng Y, Zhu J, Shen D, Qin H, Lei Z, Li W,
Liu Z and Huang JA: MicroRNA-205 targets SMAD4 in non-small cell
lung cancer and promotes lung cancer cell growth in vitro and in
vivo. Oncotarget. 8:30817–30829. 2017.PubMed/NCBI
|
|
18
|
Zhou Y, Wu D, Tao J, Qu P, Zhou Z and Hou
J: MicroRNA-133 inhibits cell proliferation, migration and invasion
by targeting epidermal growth factor receptor and its downstream
effector proteins in bladder cancer. Scand J Urol. 47:423–432.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bhardwaj A, Singh S and Singh AP:
MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs. Mol
Cell Pharmacol. 2:213–219. 2010.PubMed/NCBI
|
|
20
|
Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou
X, Zhang ZJ, Peng YH, Yang YZ and Yun JP: miR-720 inhibits tumor
invasion and migration in breast cancer by targeting TWIST1.
Carcinogenesis. 35:469–478. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang Y, Lin Y, Li C, Hu X, Liu Y, He M,
Luo J, Sun G, Wang T, Li W and Guo M: MicroRNA-720 promotes in
vitro cell migration by targeting Rab35 expression in cervical
cancer cells. Cell Biosci. 5:562015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X, Kuang Y, Shen X, Zhou H, Chen Y,
Han Y, Yuan B, Zhou J, Zhao H, Zhi Q and Xue X: Evaluation of
miR-720 prognostic significance in patients with colorectal cancer.
Tumour Biol. 36:719–727. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu Y, Liu T and Gao J: Effects of
antisense cyclin D1 expressing vector on the cell growth and
apoptosis of pancreatic carcinoma. Zhonghua Bing Li Xue Za Zhi.
27:348–351. 1998.(In Chinese). PubMed/NCBI
|
|
25
|
Yan L, Wang Y, Wang ZZ, Rong YT, Chen LL,
Li Q, Liu T, Chen YH, Li YD, Huang ZH and Peng J: Cell motility and
spreading promoted by CEACAM6 through cyclin D1/CDK4 in human
pancreatic carcinoma. Oncol Rep. 35:418–426. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee Y, Ko D, Min HJ, Kim SB, Ahn HM, Lee Y
and Kim S: TMPRSS4 induces invasion and proliferation of prostate
cancer cells through induction of Slug and cyclin D1. Oncotarget.
7:50315–50332. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mizuguchi Y, Takizawa T, Yoshida H and
Uchida E: Dysregulated miRNA in progression of hepatocellular
carcinoma: A systematic review. Hepatol Res. 46:391–406. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu H, Wang H, Liu X and Yu T: miR-1271
inhibits migration, invasion and epithelial-mesenchymal transition
by targeting ZEB1 and TWIST1 in pancreatic cancer cells. Biochem
Biophys Res Commun. 472:346–352. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ren ZG, Dong SX, Han P and Qi J: miR-203
promotes proliferation, migration and invasion by degrading SIK1 in
pancreatic cancer. Oncol Rep. 35:1365–1374. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Trehoux S, Lahdaoui F, Delpu Y, Renaud F,
Leteurtre E, Torrisani J, Jonckheere N and Van Seuningen I:
Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by
targeting the MUC1 mucin in pancreatic cancer cells. Biochim
Biophys Acta. 1853:2392–2403. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xia X, Zhang K, Cen G, Jiang T, Cao J,
Huang K, Huang C, Zhao Q and Qiu Z: MicroRNA-301a-3p promotes
pancreatic cancer progression via negative regulation of SMAD4.
Oncotarget. 6:21046–21063. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li L, Li B, Chen D, Liu L, Huang C, Lu Z,
Lun L and Wan X: miR-139 and miR-200c regulate pancreatic cancer
endothelial cell migration and angiogenesis. Oncol Rep. 34:51–58.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhong Y and Yi C: MicroRNA-720 suppresses
M2 macrophage polarization by targeting GATA3. Biosci Rep. 36:pii:
e003632016. View Article : Google Scholar
|
|
34
|
Li X, Huo X, Li W, Yang Q, Wang Y and Kang
X: Genetic association between cyclin D1 polymorphism and breast
cancer susceptibility. Tumour Biol. 35:11959–11965. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Betticher DC, Heighway J, Hasleton PS,
Altermatt HJ, Ryder WD, Cerny T and Thatcher N: Prognostic
significance of CCND1 (cyclin D1) overexpression in primary
resected non-small-cell lung cancer. Br J Cancer. 73:294–300. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kumari S, Puneet, Prasad SB, Yadav SS,
Kumar M, Khanna A, Dixit VK, Nath G, Singh S and Narayan G: Cyclin
D1 and cyclin E2 are differentially expressed in gastric cancer.
Med Oncol. 33:402016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kopparapu PK, Boorjian SA, Robinson BD,
Downes M, Gudas LJ, Mongan NP and Persson JL: Expression of cyclin
d1 and its association with disease characteristics in bladder
cancer. Anticancer Res. 33:5235–5242. 2013.PubMed/NCBI
|
|
38
|
Gansauge S, Gansauge F, Ramadani M, Stobbe
H, Rau B, Harada N and Beger HG: Overexpression of cyclin D1 in
human pancreatic carcinoma is associated with poor prognosis.
Cancer Res. 57:1634–1637. 1997.PubMed/NCBI
|
|
39
|
Li YJ and Ji XR: Relationship between the
expression of beta-cat, cyclin D1 and c-myc and the occurance and
biological behavior of pancreatic cancer. Zhonghua Bing Li Xue Za
Zhi. 32:238–241. 2003.(In Chinese). PubMed/NCBI
|
|
40
|
Kornmann M, Danenberg KD, Arber N, Beger
HG, Danenberg PV and Korc M: Inhibition of cyclin D1 expression in
human pancreatic cancer cells is associated with increased
chemosensitivity and decreased expression of multiple
chemoresistance genes. Cancer Res. 59:3505–3511. 1999.PubMed/NCBI
|
